{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-016557","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2026-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.519479+00:00","generated_at":"2026-05-15T06:22:25.893829+00:00","sec_items":["1.01","5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment","bullets":["Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.","Lbiati resigned as CEO on March 16, 2026, and as director on April 13, 2026.","Gary Stetz serves as Interim CEO effective from the separation date.","Separation includes a general release and confidentiality covenant."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-016557","json":"https://secwatch.observer/filing/0001493152-26-016557.json","markdown":"https://secwatch.observer/filing/0001493152-26-016557.md","text":"https://secwatch.observer/filing/0001493152-26-016557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226016557/0001493152-26-016557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226016557/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:22:25.893829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}